These findings have emphasized that CGRP pathway is a promising target and have led to development of migraine-specific therapies, including CGRP receptor antagonists (gepants: ubrogepant, zavegepant, rimegepant, and atogepant) and CGRP-pathway targeting monoclonal antibodies (eptinezumab, erenumab, fremanezumab, and galcanezumab) (35). This evidence concerns the gene CALCA and migraine disorder.